Could Mass Spec Overcome the CAR T Solid Tumor Barrier?
Joey Sheff explains how proteomics is revealing targets, guiding CAR design, and predicting function in solid tumors.
04/01/2026
6 min read
False
Advertisement
Related Content
Development & Clinical
Cell & Gene
Interviews
Musings From the Power List: Jason Bock
October 14, 2026
12 min read
Jason Bock shares his outlook on RNA-targeting therapies, personalized medicine, and the future of drug development
Development & Clinical
Biopharma
Interviews
Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith
October 12, 2026
8 min read
SOTIO Biotech’s CSO explains why drug developers should test their weakest assumptions early, how she builds innovative teams, and where ADCs could go next
Development & Clinical
Small Molecules
Business & Trends
The Staying Power of Small Molecules
October 8, 2026
4 min read
We asked the 2026 Power List whether newer modalities have eclipsed small molecules – and where the traditional mainstay still wins
Development & Clinical
Biopharma
Interviews
Musings from The Power List: Andres Sirulnik
October 5, 2026
4 min read
Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines